Company Overview of Cerecor Inc.
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406...
400 East Pratt Street
Baltimore, MD 21202
Founded in 2011
Key Executives for Cerecor Inc.
Co-Founder,Chief Executive Officer, President and Director
Founder, Vice Chairman and Member of Nominating & Corporate Governance Committee
Founder and Chairman of Scientific Advisory Board
Founder and Member of Scientific Advisory Board
Interim Chief Financial Officer
Compensation as of Fiscal Year 2015.
Cerecor Inc. Key Developments
Cerecor Inc. Initiates Phase 2 Study for CERC-301
Sep 3 15
Cerecor Inc. announced that it has dosed the first subject in Clin301-203, a Phase 2 study of CERC-301 as an oral, adjunctive treatment of major depressive disorder (MDD). CERC-301 is an NR2B specific, NMDA antagonist, which the Company believes has the potential to provide a rapid onset of antidepressant effect. Clin301-203 is a randomized, double blinded placebo-controlled trial designed to evaluate the antidepressant effect of 12 mg and 20 mg doses of CERC-301. The trial is expected to enroll approximately 104 subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with either a serotonin reuptake inhibitor, or SSRI, or serotonin norepinephrine reuptake inhibitor, or SNRI. Clin301-203 includes two intermittent dose administrations seven days apart, followed by 14 days of observation. The primary objective of Clin301-203 is to evaluate the antidepressant effect of CERC-301, in 12 mg and 20 mg dosages, compared to placebo as assessed by the 6-item unidimensional sub-set of the Hamilton Depression Rating Scale.
Cerecor Eyes Acquisitions
Jun 12 15
Cerecor, Inc. is looking for acquisitions. The company has filed an IPO in the amount of $31.63 million. They intend to use the net proceeds from this offering, together with their existing cash and cash equivalents, to fund the costs of Phase 2 clinical development of CERC-301 and CERC-501, preclinical research for CERC-406, research and development to build their COMTi platform and potential in licensing or other acquisitions and for working capital and general corporate purposes.
Cerecor, Inc. Auditor Raises 'Going Concern' Doubt
Jun 12 15
Cerecor, Inc. filed its Annual on Jun 12, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|